文献速递类风湿关节炎脊柱关节炎其他结缔组织病

重组带状疱疹疫苗在潜在免疫介导疾病患者中的效力与严重不良事件汇总分析

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该分析汇总ZOE-50和ZOE-70两项随机试验中入组时报告至少一种潜在免疫介导疾病且未接受免疫抑制治疗的受试者,评估重组带状疱疹疫苗预防带状疱疹的效力和严重不良事件。结果显示总体效力为90.5%(95%CI: 73.5, 97.5%),严重不良事件发生率与安慰剂组相似。

要点

  • 在报告潜在免疫介导疾病的受试者中,重组带状疱疹疫苗预防带状疱疹的总体效力为90.5%(95%CI: 73.5, 97.5%)。
  • 70-79岁年龄组效力最低,为84.4%(95%CI: 30.8, 98.3%)。
  • 严重不良事件和致死性严重不良事件在疫苗组与安慰剂组之间相似。

核心结论

  • 在入组时报告潜在免疫介导疾病的ZOE-50/70受试者中,重组带状疱疹疫苗对带状疱疹高度有效,且严重不良事件发生率与安慰剂组相似。

研究设计与样本

  • ZOE-50(NCT01165177)和ZOE-70(NCT01165229)为3期随机试验,受试者随机接受两剂重组带状疱疹疫苗或安慰剂,间隔2个月。
  • 本分析纳入入组时报告至少一种潜在免疫介导疾病且未接受免疫抑制治疗的受试者,其中疫苗组983例、安慰剂组960例。

主要发现

  • 入组时最常见的潜在免疫介导疾病为银屑病、脊柱关节炎和类风湿关节炎。
  • 在完成两剂接种且第二剂后30天内未发生确诊带状疱疹的受试者中,总体效力为90.5%(95%CI: 73.5, 97.5%)。
  • 70-79岁年龄组效力最低,为84.4%(95%CI: 30.8, 98.3%)。
  • 严重不良事件和致死性严重不良事件在疫苗组与安慰剂组之间相似。

关键数值与推荐

  • 效力分析人群为完成两剂接种且第二剂后30天内未发生确诊带状疱疹的受试者。
  • 安全性分析人群为接受至少一剂疫苗或安慰剂的全部受试者。

临床怎么用

  • 对于报告潜在免疫介导疾病且未接受免疫抑制治疗的≥50岁成人,重组带状疱疹疫苗可提供高度保护。
  • 在该人群中接种重组带状疱疹疫苗未观察到严重不良事件发生率的增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT OBJECTIVE: In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated ≥90% efficacy in preventing herpes zoster (HZ) in all age groups ≥50 years. Given the increased HZ risk associated with certain underlying autoimmune diseases or their treatment regimes, we conducted a post hoc analysis of RZV's efficacy against HZ and safety profile [specifically, the occurrence of serious adverse events (SAEs)] in ZOE-50/70 participants who reported pre-existing potential immune-mediated diseases (pIMDs) at enrolment and were not on immunosuppressive therapies. METHODS: Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomized to receive two doses of RZV or placebo 2 months apart. In this subgroup analysis of participants with at least one pIMD at enrolment, the efficacy was calculated for two-dose recipients who did not develop confirmed HZ before 30 days post-dose 2. SAE occurrence was evaluated for all participants who received at least one dose. RESULTS: Of the 14 645 RZV and 14 660 placebo recipients from the ZOE-50/70 studies, 983 and 960, respectively, reported at least one pre-existing pIMD at enrolment and were included in these analyses. The most frequent pre-existing conditions were psoriasis, spondyloarthropathy and RA. Efficacy against HZ was 90.5% (95% CI: 73.5, 97.5%) overall with the lowest being 84.4% (95% CI: 30.8, 98.3%) in the 70-79-year-old age group. SAEs and fatal SAEs were similar between RZV and placebo recipients. CONCLUSION: In ZOE-50/70 participants with pre-existing pIMDs, RZV was highly efficacious against HZ and SAE incidence was similar between RZV and placebo recipients. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01165177 (ZOE-50), NCT01165229 (ZOE-70).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Dagnew AF, Rausch D, Hervé C, et al. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021. PMID: 32910152. doi:10.1093/rheumatology/keaa424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。